People on the Move: January 2022

By Jenni Spinner

06-Jan-2022 - Last updated on 06-Jan-2022 at 16:58 GMT

(lvcandy/iStock via Getty Images Plus)

This month’s news on mergers and acquisitions, hires, and other developments includes notable firms like Altasciences, Protocol First, WuXi STA, and more.

People on the Move: January 2022

Altasciences: acquisition of Sinclair Research

IACT LMC Manna Research, True North Clinical Research: merger

Greenphire: Alan Matuszak, chief technological officer

Tools4Patient: name change to Cognivia

Protocol First, Flatiron Health: merger

Thread: Scott Pearson, chief product officer

Emmes: acquisition of Institut Dr. Schauerte

DFE Pharma: researcher recognized as Outstanding Early Career Scientist

WuXi STA: Shanghai site passes FDA inspection

Wheeler Bio: $14m in seed funding

Related tags Mergers and acquisitions Recruitment expansion Fda CRO Clinical trials Altasciences Wuxi apptec

Related news

Show more

Related products

show more

Generic method approach for determination of residual solvents in active pharmaceutical ingredients by gas chromatography

Content provided by Almac Group | 29-Nov-2023 | White Paper

Solvents are defined as organic chemicals that are used to dissolve components. They are used during the manufacture of drug substances and can also potentially...

Almac Group releases 2023 Corporate Social Responsibility Report

Content provided by Almac Group | 14-Nov-2023 | Application Note

Almac Group today announces the release of the company’s 2023 Corporate Social Responsibility report, which highlights Almac’s progress and commitments...

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Related suppliers

Follow us

Products

View more

Webinars

On-demand webinars

Headlines

Promotional Features